Symmetry Investments LP Makes New $1.34 Million Investment in Humana Inc. (NYSE:HUM)

Symmetry Investments LP purchased a new position in shares of Humana Inc. (NYSE:HUMGet Rating) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,897 shares of the insurance provider’s stock, valued at approximately $1,344,000.

A number of other large investors have also recently made changes to their positions in the business. Cordasco Financial Network grew its position in shares of Humana by 32.0% in the 3rd quarter. Cordasco Financial Network now owns 99 shares of the insurance provider’s stock worth $39,000 after acquiring an additional 24 shares in the last quarter. Moors & Cabot Inc. grew its position in shares of Humana by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 1,455 shares of the insurance provider’s stock worth $567,000 after acquiring an additional 24 shares in the last quarter. B. Riley Wealth Management Inc. grew its position in shares of Humana by 5.0% in the 4th quarter. B. Riley Wealth Management Inc. now owns 546 shares of the insurance provider’s stock worth $253,000 after acquiring an additional 26 shares in the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Humana by 4.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 592 shares of the insurance provider’s stock worth $230,000 after acquiring an additional 27 shares in the last quarter. Finally, Cribstone Capital Management LLC grew its position in shares of Humana by 2.3% in the 3rd quarter. Cribstone Capital Management LLC now owns 1,263 shares of the insurance provider’s stock worth $491,000 after acquiring an additional 28 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

A number of research analysts recently issued reports on HUM shares. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 20th. Morgan Stanley boosted their price objective on Humana from $410.00 to $436.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 9th. Deutsche Bank Aktiengesellschaft boosted their price objective on Humana from $418.00 to $435.00 in a research report on Thursday, February 3rd. UBS Group upgraded Humana from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $486.00 to $520.00 in a research report on Wednesday, April 13th. Finally, Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a $445.00 price objective for the company in a research report on Friday, February 4th. Seven research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $486.28.

In related news, CAO William Kevin Fleming sold 3,210 shares of the company’s stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $449.68, for a total transaction of $1,443,472.80. Following the transaction, the chief accounting officer now directly owns 884 shares of the company’s stock, valued at $397,517.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Timothy S. Huval sold 3,477 shares of the company’s stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $443.14, for a total value of $1,540,797.78. Following the transaction, the insider now directly owns 5,768 shares in the company, valued at $2,556,031.52. The disclosure for this sale can be found here. Insiders have sold 10,644 shares of company stock worth $4,702,360 over the last ninety days. 0.39% of the stock is owned by insiders.

HUM opened at $438.89 on Friday. Humana Inc. has a one year low of $351.20 and a one year high of $472.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.53 and a current ratio of 1.53. The stock’s fifty day moving average is $441.43 and its 200-day moving average is $434.10. The company has a market capitalization of $55.52 billion, a PE ratio of 18.62, a P/E/G ratio of 1.28 and a beta of 0.86.

Humana (NYSE:HUMGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The insurance provider reported $8.04 EPS for the quarter, topping analysts’ consensus estimates of $6.79 by $1.25. The company had revenue of $23.97 billion for the quarter, compared to the consensus estimate of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $7.67 EPS. On average, equities research analysts forecast that Humana Inc. will post 24.65 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be given a dividend of $0.7875 per share. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date is Wednesday, June 29th. Humana’s dividend payout ratio (DPR) is presently 13.36%.

About Humana (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMGet Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.